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Clinical approach of patients with systemic 
amyloidosis
Abstract
Hazenberg BPC.  Clinical approach of patients with 
systemic amyloidosis
Amyloidosis is the name of diseases characterised by 
deposition of protein fibrils with a beta-sheet structure. 
This beta-sheet structure generates affinity of amyloid 
for Congo red dye and is resistant to proteolysis. The 
main three types of systemic amyloidosis are AA (related 
to underlying chronic inflammation), AL (related to 
underlying monoclonal light chain production), and ATTR 
amyloidosis (related to old age or underlying hereditary 
mutations of transthyretin). Signs and symptoms vary 
among the three types and the treatment is different 
for each type. If a patient is suspected to have systemic 
amyloidosis, proof of the presence of amyloid in tissue 
must be obtained first and systemic involvement should 
be unequivocal. Determination of the precise type of 
amyloid is extremely important and one should start to 
detect the particular amyloid precursor. Assessment of 
size and function of vital organs and tissues is essential 
in the clinical work-up of a patient with systemic 
amyloidosis. A fast and thorough clinical evaluation is 
necessary to obtain all relevant information for prognosis 
and choice of treatment. The treatment is based on 
the “precursor-product” concept, in which the supply 
of amyloid precursor is the rate limiting step for further 
accumulation of amyloid. Effective therapy quickly 
and completely stops ongoing supply of precursor. In 
this respect, investigations such as serum amyloid P 
component (SAP) scintigraphy may help not only to 
investigate organ involvement but also response to 
treatment. The effects of therapy on both underlying 
disease and amyloidosis should be monitored frequently 
during follow-up. 
Tijdschr Nucl Geneesk 2011; 33(4):778-784 
Introduction
Amyloidosis is the name of a group of diseases characterised 
by deposition of proteinaceous fibrils with a molecular ß-sheet 
structure (1). This structure of the fibrils is responsible for its 
insolubility, resistance to proteolysis, and binding affinity for 
Congo red dye and the consequent green birefringence with 
polarised light. Amyloid fibrils are derived from a variety of 
protein precursors. The extracellular deposition of amyloid 
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fibrils in organs and tissues results in loss of function and 
often causes prominent swelling of the affected organ or 
tissue. Deposition of amyloid can be localised (produced 
in and limited to one organ or site of the body) or systemic 
(deposition in various organs and tissues throughout the 
body). The precursor protein is used for typing amyloid in the 
current classification of amyloidosis (2). Signs and symptoms 
of systemic amyloidosis differ among the various types of 
amyloidosis (1-3).  The aim of this article is to provide a clinical 
overview of systemic amyloidosis: an approach to diagnosis, 
clinical evaluation, and background of therapy. 
Systemic amyloidosis
Localised deposition of amyloid plays a still unresolved role in 
widespread diseases such as Alzheimer’s disease (ß-protein 
in the plaques) and diabetes mellitus type II (amylin in the 
islands of Langerhans). Systemic deposition of amyloid, 
however, is directly related to the grim prospects of systemic 
amyloidosis. Three major types can be distinguished (1-3).
AA amyloidosis is caused by longstanding inflammation. 
Serum amyloid A protein (SAA), an acute phase reactant, is 
the precursor. Signs of kidney disease, such as proteinuria 
(progressing to nephrotic syndrome) and loss of renal function 
(progressing to renal failure), are observed most frequently 
(in about 90% of cases). Less frequent manifestations are 
autonomic neuropathy, splenomegaly, hepatomegaly, goiter, 
and cardiomyopathy.
AL amyloidosis is caused by an, often low-grade, plasma cell 
dyscrasia. Lambda or kappa immunoglobulin light chain is 
the precursor of this type of amyloid. Clinical  manifestations 
are diverse, such as cardiomyopathy, hepatomegaly, 
splenomegaly, nephrotic syndrome, renal failure, orthostatic 
hypotension, diarrhea, peripheral and autonomic neuropathy, 
arthropathy, carpal tunnel syndrome (CTS), and glossomegaly. 
The diversity of disease manifestations is related to severity 
of deposition in the various organs and tissues.
ATTR amyloidosis is caused by many autosomal dominantly 
inherited point mutations of the precursor protein 
transthyretin (TTR). Transthyretin is the acronym of transport 
protein of thyroid hormone and retinol binding protein. About 
100 of these TTR mutations have been described, but the 
so-called TTR-Met30 mutation is seen most frequently. 
Prominent clinical manifestations are familial peripheral and 
autonomic neuropathy, but cardiomyopathy, renal failure, and 
eye involvement (vitreous opacities) are also often observed 
in the course of the disease. Severe cardiomyopathy is the 
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presenting manifestation in some TTR mutations. In very 
old age, non-mutated (“wild-type”) TTR can also act as 
amyloid precursor by a still unknown mechanism. This “wild-
type” ATTR amyloidosis (formerly called senile systemic 
amyloidosis) is characterised by a slowly progressive 
cardiomyopathy.
A fourth type is Aß2M amyloidosis that is associated with 
renal failure and longstanding (i.e. at least 5-10 years) 
dialysis with decreased clearance and elevated serum levels 
of beta-2-microglobulin (ß2M).ß2M is the precursor of this 
type of amyloid. Clinical manifestations are predominantly 
arthropathic, such as tenosynovitis, shoulder pain, CTS, 
periarticular cysts, pathological fractures, and destructive 
spondyloarthropathy. Synovial tissue biopsy is the method 
to detect this type of amyloid. Kidney transplantation stops 
the disease (4, 5). Aß2M amyloidosis is a disabling disease 
that should be recognised and treated, but can easily be 
distinguished from the main three types (AA, AL, and ATTR) 
of systemic amyloidosis because of the association with 
dialysis. The other three types are often difficult to diagnose, 
show variable involvement of many organs and tissues, and 
are challenging in finding the most appropriate treatment.
Histology is essential for diagnosis
The diagnosis of amyloid is based on showing its presence 
in tissue. Method of choice is a positive Congo red-stained 
tissue specimen showing the characteristic apple-green 
birefringence in polarised light (figure 1). Aspiration of a 
subcutaneous fat sample of the abdominal wall is the most 
elegant and least inconvenient method for this purpose, with 
a sensitivity ranging between 54% (6) and - in experienced 
Figure 1. Example of an abdominal subcutaneous fat aspirate, stained with Congo red.
A. Viewed in normal light: amyloid is stained red. Bar length is 100 µm.
B. The same specimen viewed in polarised light: amyloid shows apple-green birefringence (collagen is bluish-white).
hands - 93% (7) with a corresponding specificity of 100% 
(7). These figures are comparable with those of the well-
known rectum biopsy (7, 8). In case one of the primary biopsy 
sites (fat or rectum) is negative for amyloid and suspicion 
of amyloidosis remains strong, a biopsy of the alternate 
site is useful to increase the chance of detecting amyloid. 
A bone marrow biopsy can also be used, but has a rather 
low sensitivity of 50-60% (7, 8). If all screening biopsies 
are negative but suspicion of amyloidosis remains strong, a 
biopsy of the affected organ or tissue is indicated (1, 7, 9).
Localised or systemic deposition of amyloid 
It is important to establish whether deposition of amyloid 
is localised or systemic. Some sites of the body are almost 
exclusively involved in systemic amyloidosis, such as 
kidneys, liver, nerves, abdominal fat, and spleen. If such a 
site is positive for amyloid, one may conclude to systemic 
amyloidosis. Localised amyloid can often be found in some 
other specific sites of the body (such as eyelid, cardiac 
atria, larynx, ureter, skin, etc.). If in these cases amyloid 
is not detected elsewhere in the body one may conclude 
to localised amyloidosis. Most other sites (bone marrow, 
heart, bowel, lung, joint, etc.) are nearly always involved in 
systemic amyloidosis, but can be localised occasionally. In 
this situation it is necessary to demonstrate histological and/
or clinical presence of amyloid in two different organs or 
tissues. For this demonstration, however, it is sufficient to 
have histological proof at one site (such as bone marrow, skin, 
or rectum) and typical clinical involvement (such as nephrotic 
syndrome, hepatomegaly, macroglossia, or cardiomyopathy) 
at the other site (10).
A B
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Typing amyloid with confidence
Determination of the type of amyloid is very important. In 
the majority of cases the type of amyloid can be suspected 
from medical history and clinical picture. Amyloidosis in a 
patient with longstanding rheumatoid arthritis and nephrotic 
syndrome points to AA type. A patient with polyneuropathy 
who is member of a family with hereditary ATTR amyloidosis 
most probably also suffers from this disease. And for a 
patient with characteristic shoulder pads and glossomegaly 
it is hard to believe in a type different from AL amyloidosis. 
Nevertheless, even in patients with strong clinical evidence 
for a particular type of amyloid it is a good habit to search for 
solid confirmation of the specific type of amyloid involved. 
The clinical consequences of incorrect typing of amyloid can 
be huge, because prognosis and therapy of the three major 
types of systemic amyloidosis differ so much.
Immunohistochemistry of a biopsy is common practice by 
typing amyloid using specific antibodies. In AA amyloidosis 
this technique is sufficient, provided that sensitive and 
specific monoclonal antibodies are used, such as mc1 (10) or 
Reu.86.2 (11, 12). But in ATTR amyloidosis and especially in 
AL amyloidosis immunohistochemistry is less reliable than 
in AA amyloidosis (13). The false positive and false negative 
results may be due to heterogeneity of amyloid deposits, 
loss of epitopes in the fibril structure, lower sensitivity 
and specificity of (polyclonal) antibodies, and non-specific 
adherence of immunoglobulins to amyloid deposits or the 
background (10). One should realise that lack of a positive 
family history does not exclude ATTR amyloidosis as shown 
by a considerable number of “sporadic” cases that have been 
described (14). Therefore the presence of a TTR mutation 
must be confirmed by DNA analysis in all cases of ATTR 
amyloidosis. The only exclusion of this requirement is a slowly 
progressive amyloid cardiomyopathy at old age that is typical 
of “wild-type” ATTR amyloidosis.
In patients with AL amyloidosis a monoclonal plasma cell 
dyscrasia with overproduction of lambda or kappa light chain 
will be present. It can be detected in bone marrow (clonal 
dominance by immunophenotyping of plasma cells), urine 
(Bence Jones proteins, immunofixation of concentrated 
urine), and blood (M-protein, immunofixation, and – most 
important of all – by the free light chain assay). However, 
a monoclonal gammopathy of undetermined significance 
(MGUS) is frequently present in healthy older persons, 
about 2-4% in persons over 50 years old and even higher 
with advancing age (15). One should therefore realise that 
detection of an MGUS does not exclude other types than AL 
amyloidosis. It is important to notice that the clinical picture 
of ATTR amyloidosis and AL amyloidosis may be similar, such 
as in cases with polyneuropathy, autonomic neuropathy, 
cardiomyopathy, and carpal tunnel syndrome. In a patient with 
such a clinical picture it is therefore not sufficient to show 
the presence of a plasma cell dyscrasia but also necessary 
to exclude a TTR mutation before one can diagnose AL 
amyloidosis (14).
Immuno-electron microscopy seems to be more specific for 
typing all types of amyloid (16). A promising development 
for typing amyloid with confidence is proteomics (17). This 
development is especially useful to distinguish between 
AL and ATTR amyloid. Techniques such as two-dimensional 
(2D) polyacrylamide gel electrophoresis followed by matrix-
assisted laser desorption/ionization mass spectrometry and 
peptide mass fingerprinting (18) and laser microdissection 
and mass spectrometry (19) have high sensitivity with 
corresponding high specificity. Currently these sophisticated, 
expensive, and time-consuming techniques are only available 
in highly specialised centres, so immunohistochemistry 
remains standard for typing amyloid in daily practice.
Amyloid precursor
After typing amyloid one should look for an amyloid precursor 
in the blood. Detection of such a precursor and measuring its 
serum concentration is important for the choice of treatment. 
In AA amyloidosis the precursor is SAA, an acute phase 
protein (20). The behaviour of SAA during inflammation is 
similar to C-reactive protein (CRP), a protein that is used in 
daily practice. In ATTR amyloidosis the precursor is mutated 
TTR, which protein can be detected by isoelectric focusing 
(21). In AL amyloidosis the free light chain assay is used to 
quantify serum levels of free lambda and kappa precursor 
proteins using specific antibodies raised against epitopes that 
are hidden in the complete immunoglobulin (22).
Clinical evaluation
It is useful to obtain a clinical overview of the “amyloid load”, 
i.e. affected organs and tissues and severity of amyloid 
deposition in vital organs (such as heart, liver, and kidneys). 
One should not forget to ask for family history, impotence, 
orthostatic complaints, loss of sensibility, fatigue, weight loss, 
and bowel problems. Physical examination should also focus 
on signs such as orthostatic blood pressure, friability of skin, 
glossomegaly, arthropathy, hepatomegaly, splenomegaly, 
oedema, cardiac failure, and loss of sensibility and muscle 
strength of extremities.
A thoughtful systematic clinical approach is indicated. The 
heart can be examined with electrocardiography (signs 
of low voltage and pseudo-anteroseptal infarction), chest 
X-ray (normally sized heart despite signs of cardiac failure), 
echocardiography (thickness of septum and ventricular walls), 
MRI (wall thickness, delayed contrast-enhanced imaging), 24 
hour Holter registration (conduction, rhythm, and heart rate 
variability) and a MUGA scan (left ventricle ejection fraction). 
NT-proBNP and troponin levels in blood are extremely useful 
for assessing cardiac involvement and for risk evaluation 
(23-25). The kidneys can be examined with serum albumin, 
creatinine clearance, urine sediment and proteinuria. The 
liver can be examined with serum albumin, liver enzymes 
such as alkaline phosphatase, bilirubin, coagulation tests, and 
cholinesterase. Thyroid stimulating hormone can be used 
for the thyroid and fasting cortisol for the adrenal glands. 
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Autonomic function tests (“Ewing battery”) and heart rate 
variability can be used for evaluation of autonomic neuropathy 
(26, 27). Electromyography can be used to assess peripheral 
neuropathy. Abdominal ultrasound is useful to evaluate 
size and echogenicity of liver, spleen and kidneys. Not all 
of the examinations mentioned above need to be used, 
because often it is obvious that clinical organ involvement 
is not present at all. However, echocardiography should be 
considered in all patients, even in those without cardiac 
symptoms. The role of nuclear medicine techniques in 
diagnosis and clinical evaluation, such as serum amyloid P 
component (SAP) scintigraphy (28-31), will be discussed in 
other articles of this issue.
In 2004 at a consensus meeting in Tours, the amyloid 
community agreed upon guidelines for organ involvement, 
haematological response criteria, and organ response criteria 
that are currently used in AL amyloidosis (32). Table 1 shows 
the consensus criteria for organ involvement.
Prognosis
Prognosis is poor if the underlying precursor production 
remains untreated. The prognosis depends upon the type 
of amyloid, the severity of amyloid deposition, the number 
of vital organs affected, the presence of symptomatic 
cardiomyopathy, the severity of the associated disease, and 
the response to therapy of the underlying precursor-producing 
process. Patients with untreated AL amyloidosis have the 
worst prognosis, with a median survival of less than one year 
(1, 9). Median survival in untreated AL amyloidosis in case of 
symptomatic cardiomyopathy is 4-6 months, in case of kidney 
involvement about 2 years, and in case of CTS more than 3-4 
years. Untreated patients with AA amyloidosis have a median 
survival of 2-4 years (1, 9). Survival in AA strongly depends 
upon the activity of the underlying inflammation (33). Patients 
with untreated ATTR amyloidosis may survive up to 10-15 
years, but median survival is between 5 and 10 years (1).
Treatment
The foundation of treatment is the so-called “precursor-
product” concept (34). Central idea of this concept is that 
further growth of amyloid deposits will stop when the supply 
of necessary precursors is put to a stop. In AA amyloidosis 
treatment is aimed at decreasing SAA serum levels to 
normal basal values (below 3 mg/l). This aim can only be 
achieved by a complete suppression or eradication of the 
underlying chronic inflammation. Examples are surgical 
treatment of chronic osteomyelitis and antibiotic treatment 
of infectious diseases such as tuberculosis and leprosy. In 
Organ Criterion
Kidney 24-hr urine protein >0.5 g/day, predominantly albumin
Heart Echo: mean wall thickness >12 mm, no other cardiac cause
Liver Total liver span >15 cm in the absence of heart failure or alkaline
phosphatase >1.5 times institutional upper limit of normal
Nerve Peripheral: clinical; symmetric lower extremity sensorimotor
peripheral neuropathy
Autonomic: gastric-emptying disorder, pseudo-obstruction,
voiding dysfunction not related to direct organ infiltration
Gastrointestinal tract Direct biopsy verification with symptoms
Lung Direct biopsy verification with symptoms
Interstitial radiographic pattern
Soft tissue Tongue enlargement, clinical
Arthropathy
Claudication, presumed vascular amyloid
Skin
Myopathy by biopsy or pseudohypertrophy
Lymph node (may be localized)
Carpal tunnel syndrome
Table 1. Organ involvement: biopsy of affected organ or biopsy at an alternate site*
*Alternate sites available to confirm the histologic diagnosis of amyloidosis: fine-needle abdominal fat aspirate and/or biopsy of the minor salivary glands, rectum, or gingiva. Derived from 
Gertz et al (32).
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chronic inflammatory diseases such as rheumatoid arthritis 
and Crohn’s disease effective suppression of inflammation 
(resulting in a substantial decrease of serum SAA levels 
below 3 mg/l) is often difficult, but should be attempted (33). 
To achieve this goal, cytostatic drugs can be used (such as 
methotrexate and azathioprine), but also biologicals such as 
anti-TNF (tumour necrosis factor) drugs (such as infliximab, 
adalimumab and etanercept). In patients with TRAPS (TNF-
Receptor-Associated Periodic Syndrome), etanercept (acting 
as soluble TNF receptor) seems to be a rational treatment 
because of the abnormal function of the mutated TNF 
receptor. The interleukin-1-receptor antagonist anakinra is 
often highly effective in cryopyrin-related diseases such 
as familial cold urticaria and Muckle-Wells syndrome (35). 
Colchicine has a central place in the treatment of Familial 
Mediterranean Fever (FMF), not only by reducing the 
frequency and severity of attacks, but also by preventing the 
development of AA amyloidosis (36).
In AL amyloidosis the aim of treatment is to eradicate the 
underlying plasma cell dyscrasia by chemotherapy. High 
dose melphalan with autologous stem cell transplantation 
is favourable in a group of well-selected patients (37), but 
currently less toxic and less intensive regimens are studied 
using novel drugs such as thalidomide, lenalidomide and 
bortezomib, all combined with dexamethazone (38). In 
patients with hereditary ATTR amyloidosis liver transplantation 
is the only possibility to remove the source of 99% of the 
mutated TTR in the circulation (39). However, this approach 
is not always successful, because amyloid sometimes still 
progresses in the heart after transplantation (40, 41). 
Beside treatment aimed at the underlying disease, it is 
necessary to give supportive treatment for loss of organ 
function that is caused by amyloid deposition. Multisystem 
involvement often results in a mixture of serious problems 
and in such a situation it is almost impossible to realise an 
appropriate treatment for all symptoms (1).
Monitoring the effect of treatment
Measuring the effect of treatment is important for such an 
intangible disease as systemic amyloidosis. The expectation 
is that no further accumulation of amyloid deposits will occur 
after successful elimination of the precursor supply. Besides, 
the body itself will possibly try to remove amyloid. Repeated 
measurements will help to get an impression of the treatment 
effect. Two different processes should be monitored in this 
way.
Firstly, the underlying precursor-producing process with the 
respective precursors: serum SAA, free kappa or lambda light 
chain, and mutated ATTR in AA, AL, and ATTR amyloidosis 
respectively. If treatment is successful SAA levels should fall 
below 3 mg/l, free kappa and lambda levels and the kappa/
lambda ratio should return to the reference ranges, and 
mutant TTR should not be detectable in the blood anymore.
Secondly, there is the process of amyloid accumulation, 
measuring the clinical “amyloid load”. For this measurement 
quantitative abnormal clinical signs should be monitored, 
such as serum albumin, alkaline phosphatase, bilirubin, NT-
proBNP, troponin, creatinine clearance, proteinuria, ventricular 
wall thickness, left ventricle ejection fraction, conduction and 
rhythm, heart rate variability, Ewing battery results, and the 
sizes of enlarged organs, such as liver, spleen, and kidneys. 
The abdominal subcutaneous fat aspiration can be repeated at 
each time point to get an idea of the severity of the presence 
of amyloid or its disappearance from tissue (41-43). SAP 
scintigraphy, if abnormal at presentation, can also be used 
to monitor amyloid regression in the individual patient (44, 
45). At the consensus meeting in Tours in 2004 also a set 
of response criteria in systemic AL amyloidosis has been 
accepted (32).
Treatment perspectives
The “precursor-product” concept focuses on stopping 
ongoing deposition of amyloid. Clinical research is focused on 
developing new drugs that interfere with amyloid deposition 
or stimulate removal of amyloid deposits. Currently new 
drugs are investigated that stabilise TTR in the circulation 
and hamper deposition of amyloid, such as diflunisal and 
tafamidis. Both drugs stabilise in vitro the TTR tetramer in 
blood and prohibit its degradation into amyloidogenic dimers 
and monomers (46). However, results of clinical trials have not 
been published yet. Doxycyclin stimulates removal of ATTR 
amyloid deposits in mice (47). A promising drug for patients 
with AA amyloidosis is eprodisate (48). This drug prohibits 
binding of SAA to glycosaminoglycans in tissue (49). CPHPC 
is a drug that leads to depletion of SAP from the circulation 
(50). This mechanism possibly stops accumulation of amyloid 
and may be useful for all types of systemic amyloidosis 
(51). A completely different approach is vaccination. Early 
research was focused on conformational epitopes present in 
all types of amyloid that might be used for vaccination (52). 
The London group recently demonstrated in mice that CPHPC 
followed by anti-SAP antibodies resulted in a quick removal of 
almost all AA amyloid from the tissues (53). If this huge effect 
on amyloid turns out to be valid in human beings, it might 
dramatically change the prospects of patients with all types of 
systemic amyloidosis.
Conclusion
A systematic evaluation of patients with systemic amyloidosis 
helps to get a grip on this intangible disease. Histological 
proof of amyloid, verification of systemic involvement, 
determination of the particular type of amyloid and its 
precursor form the background of a thoughtful clinical 
evaluation. New techniques such as 123I-SAP scintigraphy 
may have a place in this evaluation. The “precursor-product” 
concept is still the current basis of treatment, but research is 
aimed at finding new ways to attack amyloid. 
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